SuperworthCryo Cell International price to book ratio CCEL
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 9.8×
- Oct 2022
- Peer median
- 1.9×
Cryo Cell International's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.
It was last meaningful in Oct 2022, at 9.8×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2022 | 9.8× | 9.8× | 20.4× |
| 2021 | 20.6× | 19.3× | 28.6× |
Against its peers
Companies in Healthcare nearest Cryo Cell International's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| CCELCryo Cell International | n/m |
| NEPHNephros | 3.2× |
| ATNMActinium Pharmaceuticals | 1.6× |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.5× |
| LFVNLifevantage | 2.2× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 1.3× |
| PDEXPro DEX | 4.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| NATRNatures Sunshine Products | 1.3× |
| Peer median | 1.9× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Cryo Cell International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.